Poolbeg Pharma granted patent by USPTO for POLB 001

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF),  a leading infectious disease focused biopharmaceutical company, has announced that further to its announcement on 4 October 2022, it has been granted a patent by the US Patent and Trademark Office (USPTO) for methods of treating hypercytokinaemia using POLB 001, a small molecule immunomodulator being developed to address the unmet medical need arising from severe influenza and other acute inflammatory conditions.

Key highlights

·      Patent granted for use of certain p38 MAP kinase inhibitors for the treatment of hypercytokinaemia

·      Allows for use in combination with an antiviral agent

·      Patent enhances the robust IP portfolio protecting Poolbeg’s growing pipeline

The USPTO granted a patent for the use of POLB 001 and related p38 MAP kinase (mitogen-activated protein kinase) inhibitors for the treatment of hypercytokinaemia (or “cytokine storm”), including hypercytokinaemia that occurs due to viral infection such as an influenza virus, cancer or an autoimmune response, through the modulation of the immune response (reducing the body’s hyperinflammatory response).

Poolbeg has a worldwide license for POLB 001 for all uses in humans and is developing a strong IP portfolio with US patent protection in place covering the use of a wide range of p38 MAP kinase (mitogen-activated protein kinase) inhibitors for the treatment of symptoms of severe influenza and hypercytokinaemia and a European patent for the class of p38 MAP kinase inhibitors for use in the treatment of severe influenza.

In January 2022, the Company filed a patent application to seek class protection for the novel use of p38 inhibitors in CAR T cell treatment. This opens up a significant new market opportunity for POLB 001 beyond severe influenza. Poolbeg continues to explore opportunities to expand its IP around this asset to cover new disease areas which could enhance the value of the asset.

The Company continues to work with its patent advisors to broaden and expand its patent families.

Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said:

“We are expanding our IP portfolio across the globe, allowing us to continue advancing and protecting our programmes for the treatment or prevention of severe influenza and hypercytokinaemia. Enhanced IP protection of our assets across key markets, such as the US, increases the overall value and attractiveness of these products to potential partners. This is particularly important in the light of the recent favourable results from our POLB 001 LPS human challenge trial announced 2 March 2023.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Poolbeg Pharma

More articles like this

Poolbeg Pharma

Poolbeg Pharma could reach €1bn valuation

Poolbeg Pharma, the Dublin-headquartered biopharmaceutical company, could reach a €1 billion valuation, according to Jeremy Skillington, its chief executive. Skillington compared the potential of Poolbeg to that of Amryt Pharma, which was sold to Chiesi Farmaceutici for $1.48

Poolbeg Pharma

The role of AI in Drug Discovery and Healthcare

Artificial intelligence (AI) has emerged as a promising solution with significant potential to revolutionize drug discovery and development. The global AI in healthcare market, valued at USD 16.3 billion in 2022, is projected to grow at a CAGR

Poolbeg Pharma

The impact of Artificial Intelligence in the pharmaceutical industry

Artificial Intelligence (AI) has emerged as a transformative force in various industries, and the field of drug discovery is no exception. AI-powered technologies have revolutionized the way pharmaceutical research is conducted, accelerating the discovery and development of new

Poolbeg Pharma

Amryt trio join Poolbeg leadership team

Poolbeg Pharma (AIM: POLB) has recruited three new members of its leadership team from Amryt Pharma, a fellow Anglo-Irish drugmaker with the same co-founder that was recently acquired by privately-held Italian drugmaker Chiesi. These experienced professionals will assume pivotal roles within

Poolbeg Pharma

Poolbeg Pharma Immunomodulator II patent granted in Japan

Poolbeg Pharma Plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that the Japanese Patent Office has notified the Company of its official decision

Poolbeg Pharma

AI is taking drug discovery by storm

Artificial intelligence (AI) and machine learning (ML) technologies are redefining the way biopharma companies discover and develop drugs. It’s not a passing phase, either. Half of the 50 biggest pharmaceutical companies have entered into partnerships or licensing agreements with AI companies

Poolbeg Pharma

Poolbeg Pharma POLB 001 LPS Challenge Trial data to be presented at IUIS

Poolbeg Pharma (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that an abstract highlighting the potential of POLB 001 as a groundbreaking therapy has been accepted

Poolbeg Pharma

Key senior members of former Amryt Pharma leadership join Poolbeg Pharma

Poolbeg Pharma announced the appointment of key former executives of Amryt Pharma plc (‘Amryt’) to its leadership team. These experienced professionals will assume pivotal roles within Poolbeg, further enhancing the Company’s expertise and capabilities. Poolbeg’s Chairman, Cathal Friel, co-founded both

Poolbeg Pharma

Former Amryt Pharma leadership team to join Poolbeg

Three members of Irish-based Amryt Pharma’s former leadership team are set to assume “pivotal roles” at London-headquartered pharma and biotech firm Poolbeg Pharma. David Allmond, John McEvoy and Laura Maher will join the company in the coming months. Allmond will become chief business officer

Poolbeg Pharma

The potential of AI in Drug Discovery and its impact on Healthcare

The discove­ry of new drugs has always been a challe­nging and expensive proce­ss. It involves extensive­ timeframes and significant costs, which have long highlighte­d the need for re­form in this critical field. Despite pre­vious efforts to accelerate drug

Poolbeg Pharma

Could AI save us from the next pandemic?

The COVID-19 pandemic was an eye opener for the world on how quickly diseases and pathogens can emerge and spread globally, wreaking havoc on societies, economies, and healthcare systems. While the pharmaceutical industry scrambled for vaccines and treatments

Poolbeg Pharma

Poolbeg Pharma partners with Nasdaq-listed biopharma company

Poolbeg Pharma has partnered with a Nasdaq-listed biopharma company on its oral delivery platform. The strategic collaboration will see both companies develop an optimised oral drug to treat a metabolic condition. Poolbeg said that it will receive funding

No more posts to show